News
Personalized mRNA cancer vaccine shows promise in extending life span in melanoma trial
Summary by The Bellaire Editorial Desk ABCNews , as published by ABC13 Houston (KTRK / ABC)
· August 19, 2026
· 1 min read
Photo: ABC13 Houston (KTRK / ABC) · view original
Story provenance No corrections
Summary created by The Bellaire Editorial Desk — automated, rule-governed Byline on source page ABCNews, as published by ABC13 Houston (KTRK / ABC) Original story Read at the source Source published Aug 19, 2026 Indexed here Aug 19, 2026 AI assistance Automated summary drawn from the source’s own published text Prepublication human review No — editorial rules, flagged-item review, and published samples
Every story comes with a passport. How we work · Corrections log · Publisher’s note
Key points Merck and Moderna announced the vaccine's success in a large, late-stage trial. A personalized mRNA-based cancer vaccine has shown promise in extending life span.
A personalized mRNA-based cancer vaccine has shown promise in extending life span. Merck and Moderna announced the vaccine's success in a large, late-stage trial. The trial involved high-risk patients with melanoma.
The vaccine is based on mRNA technology and is personalized, suggesting a tailored approach to treatment. Merck and Moderna made the announcement on Wednesday, revealing the positive outcome of the trial. Further details about the trial and the vaccine's effectiveness are available from the source.
The announcement marks a significant development in the treatment of melanoma, particularly for high-risk patients.
More News Today’s briefing Local events
Why this story is here
ABC13 Houston (KTRK / ABC) reported and published this story. The Bellaire selected it, summarised the key facts above, and links to the original. We did not report this story and we added no reporting of our own to it.
About this story
As published by ABC13 Houston (KTRK / ABC) . The Bellaire selects stories from publishers’ feeds, summarises them, and links back to the publisher that reported them. We add no reporting of our own. We attribute every source, link to the original report, and follow a documented editorial standards policy. To understand how stories are selected and reviewed, read our about page .
For the complete original report, visit ABC13 Houston (KTRK / ABC) . Have a tip or correction? Contact the editor .
Category: News Published: August 19, 2026 Source: ABC13 Houston (KTRK / ABC) Reading time: 1 min
Frequently asked about this story
What is this story about? A personalized mRNA-based cancer vaccine has shown promise in extending life span. Merck and Moderna announced the vaccine's success in a large, late-stage trial. The trial involved high-risk…
When was this published? This article was first published on August 19, 2026 by ABC13 Houston (KTRK / ABC) and curated for The Bellaire readers.
Who reported this story? This story was reported by ABCNews at ABC13 Houston (KTRK / ABC). To learn more about how The Bellaire selects and reviews stories, see our editorial standards .
Where can I find related coverage? See more News coverage from The Bellaire, or browse our daily briefing and topic hubs .
← Back to all news
More News →
Today’s briefing
Subscribe to newsletter
